Literature DB >> 26219593

Assessing cerebral glucose metabolism in patients with idiopathic rapid eye movement sleep behavior disorder.

Jingjie Ge1, Ping Wu1, Shichun Peng2, Huan Yu3, Huiwei Zhang1, Yihui Guan1, David Eidelberg2, Chuantao Zuo1, Yilong Ma2, Jian Wang3.   

Abstract

Idiopathic rapid eye movement sleep behavior disorder (RBD) is a risk marker for subsequent development of neurodegenerative parkinsonism. In this study, we aimed to investigate whether regional cerebral metabolism is altered in patients with RBD and whether regional metabolic activities are associated with clinical measurements in individual patients. Twenty-one patients with polysomnogram-confirmed RBD and 21 age-matched healthy controls were recruited to undertake positron emission tomography imaging with [(18)F]fluorodeoxyglucose. Differences in normalized regional metabolism and correlations between metabolic activity and clinical indices in RBD patients were evaluated on a voxel basis using statistic parametric mapping analysis. Compared with controls, patients with RBD showed increased metabolism in the hippocampus/parahippocampus, cingulate, supplementary motor area, and pons, but decreased metabolism in the occipital cortex/lingual gyrus (P<0.001). RBD duration correlated with metabolism positively in the anterior vermis (r=0.55, P=0.01), but negatively in the medial frontal gyrus (r=-0.59, P=0.005). In addition, chin electromyographic activity presented a positive metabolic correlation in the hippocampus/parahippocampus (r=0.48, P=0.02), but a negative metabolic correlation in the posterior cingulate (r=-0.61, P=0.002). This study has suggested that region-specific metabolic abnormalities exist in RBD patients and regional metabolic activities are associated with clinical measures such as RBD duration and chin electromyographic activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26219593      PMCID: PMC4671128          DOI: 10.1038/jcbfm.2015.173

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  40 in total

1.  Decreased striatal dopaminergic innervation in REM sleep behavior disorder.

Authors:  R L Albin; R A Koeppe; R D Chervin; F B Consens; K Wernette; K A Frey; M S Aldrich
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

Review 2.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

Authors:  Heiko Braak; Kelly Del Tredici; Hansjürgen Bratzke; John Hamm-Clement; Daniele Sandmann-Keil; Udo Rüb
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

3.  Abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

Review 4.  Breakdown in REM sleep circuitry underlies REM sleep behavior disorder.

Authors:  John Peever; Pierre-Hervé Luppi; Jacques Montplaisir
Journal:  Trends Neurosci       Date:  2014-03-24       Impact factor: 13.837

5.  Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study.

Authors:  A R Braun; T J Balkin; N J Wesenten; R E Carson; M Varga; P Baldwin; S Selbie; G Belenky; P Herscovitch
Journal:  Brain       Date:  1997-07       Impact factor: 13.501

6.  Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder.

Authors:  Mélanie Vendette; Jean-François Gagnon; Jean-Paul Soucy; Nadia Gosselin; Ronald B Postuma; Maria Tuineag; Isabelle Godin; Jacques Montplaisir
Journal:  Mov Disord       Date:  2011-05-03       Impact factor: 10.338

7.  Population-based norms for the Mini-Mental State Examination by age and educational level.

Authors:  R M Crum; J C Anthony; S S Bassett; M F Folstein
Journal:  JAMA       Date:  1993-05-12       Impact factor: 56.272

Review 8.  Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study.

Authors:  C C Hong; J C Gillin; B M Dow; J Wu; M S Buchsbaum
Journal:  Sleep       Date:  1995-09       Impact factor: 5.849

9.  Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

Authors:  C H Schenck; S R Bundlie; M W Mahowald
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

10.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

Authors:  K Stiasny-Kolster; Y Doerr; J C Möller; H Höffken; T M Behr; W H Oertel; G Mayer
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

View more
  16 in total

1.  Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Zhemin Huang; Chengfeng Jiang; Ling Li; Qian Xu; Jingjie Ge; Ming Li; Yihui Guan; Jianjun Wu; Jian Wang; Chuantao Zuo; Huan Yu; Ping Wu
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-10       Impact factor: 6.200

Review 2.  Update on Molecular Imaging in Parkinson's Disease.

Authors:  Zhen-Yang Liu; Feng-Tao Liu; Chuan-Tao Zuo; James B Koprich; Jian Wang
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

3.  [Changes of brain structural network properties in patients with rapid eye movement sleep behavior disorder].

Authors:  Ruirui Zhang; Zhonglin Li; Yingying Bai; Pengfei Xu; Jiewen Zhang; Hongju Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

Review 4.  Neuroimaging in pre-motor Parkinson's disease.

Authors:  Thomas R Barber; Johannes C Klein; Clare E Mackay; Michele T M Hu
Journal:  Neuroimage Clin       Date:  2017-04-21       Impact factor: 4.881

Review 5.  Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies.

Authors:  Matej Skorvanek; Eva Feketeova; Monica M Kurtis; Jan Rusz; Karel Sonka
Journal:  Front Neurol       Date:  2018-05-25       Impact factor: 4.003

6.  Validation of abnormal glucose metabolism associated with Parkinson's disease in Chinese participants based on 18F-fluorodeoxyglucose positron emission tomography imaging.

Authors:  Rongbing Jin; Jingjie Ge; Ping Wu; Jiaying Lu; Huiwei Zhang; Jian Wang; Jianjun Wu; Xianhua Han; Weishan Zhang; Chuantao Zuo
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-06       Impact factor: 2.570

7.  Characterizing the heterogeneous metabolic progression in idiopathic REM sleep behavior disorder.

Authors:  Xianhua Han; Ping Wu; Ian Alberts; Hucheng Zhou; Huan Yu; Panagiotis Bargiotas; Igor Yakushev; Jian Wang; Guenter Höglinger; Stefan Förster; Claudio Bassetti; Wolfgang Oertel; Markus Schwaiger; Sung-Cheng Huang; Paul Cumming; Axel Rominger; Jiehui Jiang; Chuantao Zuo; Kuangyu Shi
Journal:  Neuroimage Clin       Date:  2020-05-26       Impact factor: 4.881

Review 8.  Neurophysiological basis of rapid eye movement sleep behavior disorder: informing future drug development.

Authors:  Poul Jennum; Julie Ae Christensen; Marielle Zoetmulder
Journal:  Nat Sci Sleep       Date:  2016-04-15

9.  Alterations of Brain Structural Network in Parkinson's Disease With and Without Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Tao Guo; Xiaojun Guan; Qiaoling Zeng; Min Xuan; Quanquan Gu; Peiyu Huang; Xiaojun Xu; Minming Zhang
Journal:  Front Neurol       Date:  2018-05-11       Impact factor: 4.003

10.  Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells.

Authors:  Amy M Smith; Constanze Depp; Brent J Ryan; Geoffrey I Johnston; Javier Alegre-Abarrategui; Samuel Evetts; Michal Rolinski; Fahd Baig; Claudio Ruffmann; Anna Katharina Simon; Michele T M Hu; Richard Wade-Martins
Journal:  Mov Disord       Date:  2018-10-07       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.